Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study

Guselkumab is an IL‐23 inhibitor that has been demonstrated to be effective and safe for the treatment of moderate‐to‐severe plaque psoriasis in clinical trials. The data pool relating to the use of guselkumab in a real‐life setting is still lacking. To evaluate the efficacy and safety of guselkumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Zenone, Mattia, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786539/
https://www.ncbi.nlm.nih.gov/pubmed/35762118
http://dx.doi.org/10.1111/dth.15670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786539/
https://www.ncbi.nlm.nih.gov/pubmed/35762118
http://dx.doi.org/10.1111/dth.15670

Ejemplares similares